In our original publication,1 the overall survival data that were reported contained minor inaccuracies in the external validation cohort. The corrected overall survival data are provided herein.
For fit patients, median overall survival (OS) was not reached and 5-year OS was 79% (95% CI: 73-84%). Five-year OS was 38% (95% CI: 33-42%) for unfit patients and 4% (95% CI: 0-24%) for frail patients.
The correct Figure 3, presented here, includes the number at risk at five years. The new Online Supplementary Figure S7 (see below) includes the number at risk at five years.
Correct Figure 3.Progression-free and overall survival up until five years according to frailty groups in the external validation cohort. (A) All patients. (B) Patients with limited disease. (C) Patients with advanced disease.
Correct Online Supplementary Figure S7.
Progression-free and overall survival up until five years according to frailty groups in the patients from the validation cohort with complete treatment data. (A) All patients. (B) Patients with limited disease. (C) Patients with advanced disease.
Footnotes
- Received February 25, 2026
- Accepted February 25, 2026
Correspondence
References
- Lia K, Jørgensen RRK, Wikman P. A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma. Haematologica. 2025; 110(10):2356-2366. https://doi.org/10.3324/haematol.2025.287509Google Scholar
Figures & Tables
Article Information
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.